Focus Partners Advisor Solutions LLC Buys 3,044 Shares of Amgen Inc. $AMGN

Focus Partners Advisor Solutions LLC raised its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 42.1% in the fourth quarter, Holdings Channel reports. The fund owned 10,278 shares of the medical research company’s stock after acquiring an additional 3,044 shares during the period. Focus Partners Advisor Solutions LLC’s holdings in Amgen were worth $3,364,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Dogwood Wealth Management LLC lifted its holdings in shares of Amgen by 275.0% during the fourth quarter. Dogwood Wealth Management LLC now owns 75 shares of the medical research company’s stock valued at $25,000 after acquiring an additional 55 shares during the period. Anfield Capital Management LLC lifted its holdings in shares of Amgen by 1,000.0% during the fourth quarter. Anfield Capital Management LLC now owns 77 shares of the medical research company’s stock valued at $25,000 after acquiring an additional 70 shares during the period. Board of the Pension Protection Fund bought a new position in shares of Amgen during the fourth quarter valued at $26,000. Manning & Napier Advisors LLC lifted its holdings in shares of Amgen by 49.2% during the fourth quarter. Manning & Napier Advisors LLC now owns 97 shares of the medical research company’s stock valued at $32,000 after acquiring an additional 32 shares during the period. Finally, Olistico Wealth LLC bought a new position in shares of Amgen during the fourth quarter valued at $33,000. 76.50% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on AMGN shares. Jefferies Financial Group started coverage on Amgen in a research note on Tuesday, March 10th. They issued a “hold” rating and a $350.00 target price for the company. Erste Group Bank restated a “hold” rating on shares of Amgen in a research note on Tuesday, May 5th. Argus decreased their price objective on shares of Amgen from $400.00 to $375.00 and set a “buy” rating on the stock in a report on Wednesday, May 20th. Piper Sandler decreased their price objective on shares of Amgen from $432.00 to $427.00 and set an “overweight” rating on the stock in a report on Thursday, May 14th. Finally, Wall Street Zen lowered shares of Amgen from a “buy” rating to a “hold” rating in a report on Saturday. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, fourteen have issued a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $354.12.

Insiders Place Their Bets

In other Amgen news, SVP Nancy A. Grygiel sold 1,237 shares of the business’s stock in a transaction dated Monday, May 4th. The stock was sold at an average price of $323.73, for a total transaction of $400,454.01. Following the completion of the sale, the senior vice president directly owned 7,009 shares of the company’s stock, valued at approximately $2,269,023.57. The trade was a 15.00% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Corporate insiders own 0.85% of the company’s stock.

Amgen Stock Performance

Shares of NASDAQ:AMGN opened at $344.57 on Wednesday. The stock has a market capitalization of $185.97 billion, a P/E ratio of 23.98, a P/E/G ratio of 3.47 and a beta of 0.42. Amgen Inc. has a 1-year low of $267.83 and a 1-year high of $391.29. The company has a current ratio of 1.26, a quick ratio of 1.01 and a debt-to-equity ratio of 5.65. The business has a 50-day moving average price of $341.12 and a two-hundred day moving average price of $345.52.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Thursday, April 30th. The medical research company reported $5.15 earnings per share for the quarter, topping the consensus estimate of $4.77 by $0.38. The firm had revenue of $8.62 billion during the quarter, compared to analysts’ expectations of $8.58 billion. Amgen had a return on equity of 137.41% and a net margin of 20.96%.The company’s quarterly revenue was up 5.8% compared to the same quarter last year. During the same period in the previous year, the business posted $4.90 EPS. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. Equities analysts predict that Amgen Inc. will post 22.38 earnings per share for the current year.

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.